Clinical Trials

We are currently participating in the following clinical trials:
(Click on trials for additional information from the National Institutes of Health.)

ALZHEIMER'S DISEASE STUDIES

DAYBREAK Study: Study of LY3314814 in Mild Alzheimer's Dementia
Multicenter, randomized, parallel-group, 78-week double blind, placebo-controlled, study of LY3314814 in patients with mild Alzheimer's dementia, followed by a 78-week delayed-start period. LY3314814 is a brain-permeable inhibitor being developed for the modification of the clinical course of Alzheimer's disease by slowing disease progression in patients diagnosed with early Alzheimer's dementia.
Sponsor: Eli Lilly & Co
Enrollment period: Follow up phase

Engage Study: A Study of Aducanumab (BIIB037) in Early Alzheimer's Disease (ENGAGE)
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease with administration of Aducanumab IV monthly for 2 years, followed with open extension study.
Sponsor: Biogen
Enrollment period: Follow up phase

SERENE Study: Treatment of Agitation and Aggression in Alzheimer's Disease
Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's disease.
Sponsor: ACADIA Pharmaceuticals
Enrollment period: Open

Mission AD1: A 24-Month Study to Evaluate the Efficacy and Safety of E2609 in Subjects With Early Alzheimer's Disease
Multicenter, double-blind, placebo-controlled, parallel group, in participants with Early Alzheimer's Disease (EAD) including mild cognitive impairment (MCI) due to AD/Prodromal AD and the early stages of mild AD will be conducted to evaluate the efficacy and safety of Elenbecestat.
Sponsor: Eisai Co
Enrollment period: Follow up phase

Trial of Verubecestat in Participants With Prodromal Alzheimer's Disease (APECS)
Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 in Subjects With Amnestic Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal AD), for 2 year, followed with 5 years of open label extension.
Sponsor: Merck Sharp & Dohme Corp
Enrollment period: Follow up phase

MIGRAINE STUDIES

PROMISE 1 STUDY: A Multicenter Assessment of ALD403 in Frequent Episodic Migraine
To evaluate ALD403 in patients with Frequent Episodic Migraines via IV every three months for one year. ALD403 is a CGRP antagonist for the prophylaxis of migraines. CGRP is thought to play an important role in migraine.
Sponsor: Alder
Enrollment period: Follow up phase

PARKINSON'S DISEASE STUDIES

Twelve Month Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
A 12 Month, Dose-Level Blinded Study Investigating the Safety and Efficacy of CVT 301 (Levodopa Inhalation Powder) in Parkinson's Disease Patients With Motor Response Fluctuations (OFF Phenomena).
Sponsor: Acorda Therapeutics
Enrollment period: Follow up phase

MULTIPLE SCLEROSIS STUDIES

PASSAGE STUDY: Study in Patients With Multiple Sclerosis Treated with Fingolimod
Study in patients with relapsing forms of MS, either newly treated with Fingolimod or receiving another disease-modifying therapy, to further explore the incidence of selected safety related outcomes and to further monitor the overall safety profile of Fingolimod under conditions of routine medical practice.
Sponsor: Novartis Pharmaceuticals
Enrollment period: Open





381 E. Imperial Highway
Fullerton, CA 92835

Ph (714) 879-7200
Fax (714) 879-1055



Why participate in a clinical trial?

Privacy Policy / 2019 © All Rights Reserved